Garda Capital Partners’s Moderna MRNA Stock Holding History

Garda Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,699	Closed	-$1.23M	–	397
2024 Q3	$1.72M	Buy	+25,699	New	+$2.36M	0.05%	331
2023 Q4	–	Sell	-24,453	Closed	-$2.06M	–	627
2023 Q3	$2.53M	Buy	24,453 +10,982	+82%	+$1.23M	0.12%	173
2023 Q2	$1.64M	Buy	13,471 +12,181	+944%	+$1.62M	0.09%	204
2023 Q1	$198K	Buy	+1,290	New	+$213K	0.01%	309

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Garda Capital Partners's MRNA Position: Q4 2024 in Review

Garda Capital Partners sold out of Moderna (MRNA) in Q4 2024, closing a stake of 25,699 shares — an estimated $1.23M sold.

Garda Capital Partners first reported a position in MRNA in Q1 2023 and held it in 4 quarters. The position peaked at $2.53M in Q3 2023. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

Garda Capital Partners reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
Garda Capital Partners sold 25,699 Moderna shares in Q4 2024, an estimated $1.23M.
Garda Capital Partners first reported a position in Moderna in Q1 2023 and held it in 4 quarters.
Garda Capital Partners's Moderna position peaked at $2.53M in Q3 2023.
745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Garda Capital Partners's 13F filing for Q4 2024, filed 5 Feb 2025.